<DOC>
	<DOC>NCT02509598</DOC>
	<brief_summary>Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek and compared with VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 17 years.</brief_summary>
	<brief_title>A Study Comparing LymphoseekÂ® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<mesh_term>Technetium Tc 99m Pentetate</mesh_term>
	<criteria>The subject's parent(s)/legal guardian(s) understand(s) and voluntarily signed an informed consent document prior to any studyrelated assessments/procedures being conducted. Where locally applicable, the subject also understands and voluntarily provides his/her assent prior to any studyrelated assessments/procedures being conducted Subject has been diagnosed with melanoma, rhabdomyosarcoma, or other tumor where tumor resection or biopsy is planned and lymph node mapping is appropriate The subject is clinically node negative (cN0) at the time of screening Age &lt; 18 years Male subjects of childbearing potential must be willing to use a condom during sexual intercourse and shall not father a child during the course of the study or will practice complete abstinence while on study Female subjects of childbearing potential must agree to the use of two physicianapproved contraceptive methods simultaneously or practice complete abstinence while on study The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy Has had previous surgery or radiation to node basins that would be involved in the intraoperative lymph node mapping (ILM) procedure Has a known allergy to VBD or dextran Has a history of alcohol abuse or alcohol dependency in the 3 years before study entry, or is an alcoholic or drug addict, as determined by the investigator Before the administration of Lymphoseek, has received any radiopharmaceutical within 7 radioactive halflives of that radiopharmaceutical Is scheduled for additional surgery other than the primary surgical intervention within the 7 days after Lymphoseek administration Has rhabdomyosarcoma of the intrathorasic region</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>